Lorundrostat Effective for Lowering BP in Uncontrolled Hypertension

Changes in office systolic BP of −14.1, −13.2, −6.9, and −4.1 mm Hg seen with 100, 50, 12.5 mg once daily of lorundrostat and placebo

high blood pressure
Adobe Stock

FRIDAY, Sept. 15, 2023 (HealthDay News) -- The aldosterone synthase inhibitor lorundrostat is effective for lowering blood pressure among individuals with uncontrolled hypertension, according to a study published online Sept. 10 in the Journal of the American Medical Association to coincide with the American Heart Association Hypertension 2023 Scientific Sessions, held from Sept. 7 to 10 in Boston.

Luke J. Laffin, M.D., from the Cleveland Clinic Foundation, and colleagues compared the safety and efficacy of lorundrostat with placebo in a randomized trial among adults with uncontrolled hypertension taking two or more antihypertensive medications. An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled and randomly assigned to placebo or one of five doses of lorundrostat; 37 participants with PRA greater than 1.0 ng/mL/h were subsequently enrolled and randomly assigned to placebo or lorundrostat 100 mg once daily.

The researchers observed changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg with 100, 50, and 12.5 mg once daily of lorundrostat and placebo, respectively, following eight weeks of treatment in participants with suppressed PRA. In individuals receiving twice-daily doses of 25 and 12.5 mg of lorundrostat, observed reductions in systolic blood pressure were −10.1 and −13.8 mm Hg, respectively. The least-squares mean difference in systolic blood pressure between placebo and treatment was −9.6 and −7.8 mm Hg, respectively, for the 50- and 100-mg once-daily dose. Systolic blood pressure decreased by 11.4 mm Hg among participants without suppressed PRA receiving 100 mg once-daily lorundrostat, which was similar to the blood pressure reduction with the same dose among those with suppressed PRA.

"The trial results support further study of lorundrostat as a treatment for uncontrolled hypertension," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Mineralys Therapeutics, which manufactures lorundrostat and funded the trial.

Abstract/Full Text


More Information

Elana Gotkine

Elana Gotkine

Medically reviewed by Mark Arredondo, M.D.

Published on September 15, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ